ANGELINE VERCAUTEREN: Open Payments
NPI 1407287543 · MILWAUKEE, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$655 in 29 payments from 10 companies in 2025. Trend: 2023 $408 · 2024 $488 · 2025 $655
Food & beverage: $655
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 8 | $160 |
| Alexion Pharmaceuticals, Inc. | 1 | $121 |
| Alkermes, Inc. | 5 | $103 |
| Teva Pharmaceuticals USA, Inc. | 4 | $68 |
| Lundbeck LLC | 3 | $67 |
| ABBVIE INC. | 4 | $59 |
| E.R. Squibb & Sons, L.L.C. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Janssen Pharmaceuticals, Inc | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
Products named: INGREZZA, ARISTADA, VRAYLAR, ABILIFY ASIMTUFII, UZEDY, AUSTEDO XR, COBENFY, Auvelity.
Industry payments across WI — which companies pay providers there.
